Gilead Sciences, Inc. (GILD) Position Held by Quantum Capital Management LLC NJ
Quantum Capital Management LLC NJ maintained its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 9,500 shares of the biopharmaceutical company’s stock at the close of the second quarter. Quantum Capital Management LLC NJ’s holdings in Gilead Sciences were worth $672,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Seizert Capital Partners LLC lifted its holdings in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares in the last quarter. Investment Centers of America Inc. lifted its holdings in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares in the last quarter. Fagan Associates Inc. lifted its holdings in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 845 shares in the last quarter. Capital Asset Advisory Services LLC purchased a new stake in shares of Gilead Sciences in the second quarter valued at about $875,000. Finally, First PREMIER Bank lifted its holdings in shares of Gilead Sciences by 9.0% in the second quarter. First PREMIER Bank now owns 21,533 shares of the biopharmaceutical company’s stock valued at $1,524,000 after purchasing an additional 1,787 shares in the last quarter. Institutional investors own 76.30% of the company’s stock.
Shares of Gilead Sciences, Inc. (GILD) opened at $72.13 on Tuesday. The firm has a market cap of $93,860.00, a price-to-earnings ratio of 7.56, a P/E/G ratio of -1.21 and a beta of 1.13. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a net margin of 42.22% and a return on equity of 57.15%. The firm’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same period last year, the business earned $2.75 EPS. equities analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Shareholders of record on Friday, December 15th will be issued a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.88%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is currently 23.66%.
In other Gilead Sciences news, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total transaction of $4,991,400.00. Following the completion of the transaction, the executive vice president now directly owns 62,715 shares of the company’s stock, valued at approximately $5,217,260.85. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the transaction, the chief financial officer now directly owns 43,352 shares of the company’s stock, valued at $3,684,920. The disclosure for this sale can be found here. Over the last three months, insiders have sold 666,819 shares of company stock valued at $52,303,086. 1.30% of the stock is owned by company insiders.
Several analysts have issued reports on the stock. Leerink Swann upped their price target on shares of Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a report on Thursday, October 19th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price target (up previously from $72.00) on shares of Gilead Sciences in a report on Thursday, July 27th. BidaskClub downgraded shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Cowen and Company reaffirmed an “outperform” rating and issued a $90.00 price target on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $86.00 price target (up previously from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $84.87.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.